Biotech Values

[DewDiligence]

>> After replaying the webcast, I think the only problem with the presentation was Levitt's poor speaking ability and preparedness. Otherwise the early data from 207 is promising, and the rest of the presentation (even though we've heard it many times) was status quo. <<

richter: I’m not taking off any points for Dr, Levitt’s poor speaking style –it’s the content of the speech that I’m interested in.

I respectfully disagree that the R&R talk was mostly “status quo” –I think the talk may be signaling some consequential changes. Regards, Dew